



Liquidia Technologies Contact:
Elle Pishny
919-451-1345
elle.pishny@liquidia.com

Liquidia Founder Receives Impact Entrepreneur Award

Research Triangle Park, NC — January 16, 2008— Professor Joseph DeSimone, Liquidia Technologies founder and Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill and Chemical Engineering at North Carolina State University, has been named a Triangle Impact Entrepreneur for his contributions to innovative nanoparticle therapeutics and a targeted drug delivery platform at Liquidia Technologies.

“Joe has an uncanny ability to understand the convergence of different technologies and the opportunities that convergence opens for disruptive biomedical research and product development,” says Luke Roush, Vice President of Business Development at Liquidia. “Liquidia’s PRINT™ platform, which is currently being applied to overcome serious challenges for *in vivo* delivery of nucleic acids, is one example of a technology arising from Joe’s insights. The potential for RNAi-based therapeutics is tremendous, and seeing Joe’s research begin to solve this unmet need is very exciting for our partners and investors.”

DeSimone has been involved with a number of successful ventures, including Bioabsorbable Vascular Solutions (acquired by Guidant in 2003), which he co-founded in 2002 with Richard Stack, William Starling, and Robert Langer to develop polymeric drug eluting stents for cardiovascular applications. Additionally, Dr. DeSimone has authored over 220 articles and filed more than 100 issued patents.

Business Leader magazine selected 24 local entrepreneurs for the Impact Entrepreneur award based on their tremendous achievements and contributions to innovation in the Triangle business community. DeSimone will be honored at a gala on March 3rd in Raleigh, N.C.

About Liquidia

Liquidia Technologies Inc. is a privately held nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a wide variety of life and materials science applications. Within the life sciences business, Liquidia is initially focused on the delivery of nucleic acids to treat disease and targeted therapeutics for the treatment of cancer. In the Materials Science sector, Liquidia is developing nanoscale patterned optical films for use in display technologies and photovoltaic devices. Liquidia’s proprietary PRINT™ platform is unique in its ability to replicate and produce nanoscale features with independent control of feature size, shape, and chemical composition. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina. In March 2007 Liquidia raised \$16 million in a Series B round of financing led by New Enterprise Associates. For additional information, please visit www.liquidia.com.

###